Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an ...

The response rate was higher in those with a KRAS mutation at 44%, compared to 17% in KRAS wild-type patients.

Verastem Oncology releases primary results from phase 2 RAMP 201 trial of Avutometinib in combo with defactinib: Boston Tuesday, July 15, 2025, 09:00 Hrs [IST] Verastem Oncology, ...

Verastem has two partnered RAMP programs that are targeting KRAS G12C-mutant NSCLC. RAMP 203 is in a Phase I/II trial of avutometinib in combination with Amgen’s KRAS G12C inhibitor LUMAKRAS.

Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed ...

Verastem (VSTM) said late Tuesday it has dosed the first patient in its US phase 1/2a trial of VS-73 Verastem Oncology jumps 22% on FDA nod for Avmapki Fakzynja, the first approved KRAS-mutant LGSOC ...

Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven ...

BOSTON, December 18, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced preliminary clinical data ...

Verastem (VSTM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Verastem Inc. Annual stock financials by MarketWatch. View the latest VSTM financial statements, income statements and financial ratios.

Verastem shares surge more than 50% after pancreatic-cancer treatment study data Last Updated: May 23, 2024 at 6:58 p.m. ET First Published: May 23, 2024 at 6:47 p.m. ET Share ...